Suntrust Banks’s Alaunos Therapeutics TCRT Stock Holding History

Suntrust Banks’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-81	Closed	-$23K	–	1328
2018 Q4	$23K	Buy	+81	New	+$32K	﹤0.01%	1241

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Suntrust Banks's TCRT Position: Q1 2019 in Review

Suntrust Banks sold out of Alaunos Therapeutics (TCRT) in Q1 2019, closing a stake of 81 shares — an estimated $23K sold.

Suntrust Banks first reported a position in TCRT in Q4 2018 and held it in 1 quarter. The position peaked at $23K in Q4 2018. 124 funds tracked by Wall St. Rank hold TCRT as of Q1 2019.

Suntrust Banks reported no remaining Alaunos Therapeutics position as of Q1 2019 after selling out during the quarter.
Suntrust Banks sold 81 Alaunos Therapeutics shares in Q1 2019, an estimated $23K.
Suntrust Banks first reported a position in Alaunos Therapeutics in Q4 2018 and held it in 1 quarter.
Suntrust Banks's Alaunos Therapeutics position peaked at $23K in Q4 2018.
124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2019.

Based on Suntrust Banks's 13F filing for Q1 2019, filed 15 May 2019.